# A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.

> **NCT04256434** · PHASE1 · COMPLETED · sponsor: **Lumosa Therapeutics Co., Ltd.** · enrollment: 24 (actual)

## Conditions studied

- Health

## Interventions

- **DRUG:** Dinalbuphine sebacate
- **DRUG:** Nalbuphine HCl

## Key facts

- **NCT ID:** NCT04256434
- **Lead sponsor:** Lumosa Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-31
- **Primary completion:** 2020-05-29
- **Final completion:** 2020-05-29
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04256434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04256434, "A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04256434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*